Literature DB >> 8725720

Role of the A+ helix in heparin binding to protein C inhibitor.

M G Elisen1, M H Maseland, F C Church, B N Bouma, J C Meijers.   

Abstract

Interactions between proteins and heparin(-like) structures involve electrostatic forces and structural features. Based on charge distributions in the linear sequence of protein C inhibitor (PCI), two positively charged regions of PCI were proposed as possible candidates for this interaction. The first region, the A+ helix, is located at the N-terminus (residues 1-11), whereas the second region, the H helix, is positioned between residues 264 and 280 of PCI. Competition experiments with synthetic peptides based on the sequence of these regions demonstrated that the H helix has the highest affinity for heparin. In contrast to previous observations we found that the A+ helix peptide competed for the interaction of PCI with heparin, but its affinity was much lower than that of the H helix peptide. Recombinant PCI was also used to investigate the role of the A+ helix in heparin binding. Full-length (wild-type) rPCI as well as an A+ helix deletion mutant of PCI (rPCI-delta 2-11) were expressed in baby hamster kidney cells and both had normal inhibition activity with activated protein C and thrombin. The interaction of the recombinant PCIs with heparin was investigated and compared to plasma PCI. The A+ helix deletion mutant showed a decreased affinity for heparin in inhibition reactions with activated protein C and thrombin, but had similar association constants compared to wild-type rPCI. The synthetic A+ helix peptide competed with rPCI-delta w-11 for binding to heparin. This indicated that the interaction between PCI and heparin is fairly non-specific and that the interaction is primarily based on electrostatic interactions. In summary, our data suggest that the H helix of PCI is the main heparin binding region of PCI, but the A+ helix increases the overall affinity for the PCI-heparin interaction by contributing a second positively charged region to the surface of PCI.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725720

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Suggestions on leading an academic research laboratory group.

Authors:  Frank C Church
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

2.  N-glycans of human protein C inhibitor: tissue-specific expression and function.

Authors:  Wei Sun; Paola Grassi; Ake Engström; Sanjeewani Sooriyaarachchi; Wimal Ubhayasekera; Julius Hreinsson; Kjell Wånggren; Gary F Clark; Anne Dell; Sophia Schedin-Weiss
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

3.  Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.

Authors:  Anne-Cornélie J M de Pont; Kamran Bakhtiari; Barbara A Hutten; Evert de Jonge; Margreeth B Vroom; Joost C M Meijers; Harry R Büller; Marcel Levi
Journal:  Crit Care       Date:  2005-07-21       Impact factor: 9.097

4.  Protein C inhibitor--a novel antimicrobial agent.

Authors:  Erik Malmström; Matthias Mörgelin; Martin Malmsten; Linda Johansson; Anna Norrby-Teglund; Oonagh Shannon; Artur Schmidtchen; Joost C M Meijers; Heiko Herwald
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

5.  A+-helix of protein C inhibitor (PCI) is a cell-penetrating peptide that mediates cell membrane permeation of PCI.

Authors:  Hanjiang Yang; Felix Christof Wahlmüller; Bettina Sarg; Margareta Furtmüller; Margarethe Geiger
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.